Optimer Pharmaceuticals Closes Common Share Offering
March 2, 2010 (FinancialWire) — Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) has closed a public offering of 4,887,500 shares of its common stock, including 637,500 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriter.
Jefferies & Co. (NYSE: JEF) acted as sole book-running manager.
Optimer saw net proceeds of around $51.5 million.
California-based Optimer Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing anti-infective products to treat serious infections and address unmet medical needs.
Optimer has two late-stage anti-infective product candidates under development.
FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).
FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.